Second Generation Travoprost Intracameral Implant (TREX): payments to doctors
Payments that named Second Generation Travoprost Intracameral Implant (TREX) as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $58K
- Providers
- 1
- Transactions
- 2
- Average per transaction
- $29,000
The per-transaction average — $29,000 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1 providers the average total is $58,000, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Glaukos Corporation | $58,000 | 100.0% |